Fennec Pharmaceuticals Inc. (FENC) Insider Trading Activity

NASDAQ$7.59
Market Cap
$209.1M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
311 of 892
Rank in Industry
176 of 510

FENC Insider Trading Activity

FENC Median Price and Trade Amounts History Chart

Statistics of Insider Transactions

Amount of Insider Buys and Sells

Buys
$104,602
2
8
Sells
$11,405,812
23
92

Related Transactions

Hackman Jeffrey S.Chief Executive Officer
2
$104,602
0
$0
$104,602
RALLIS CHRIS Adirector
0
$0
3
$34,236
$-34,236
Raykov Rostydirector
0
$0
13
$1.03M
$-1.03M
Southpoint Capital Advisors LP10 percent owner
0
$0
7
$10.34M
$-10.34M

About Fennec Pharmaceuticals Inc.

Fennec Pharmaceuticals Inc. operates as a biopharmaceutical company. Its product candidate in the clinical stage of development is PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.

Insider Activity of Fennec Pharmaceuticals Inc.

Over the last 12 months, insiders at Fennec Pharmaceuticals Inc. have bought $104,602 and sold $11.41M worth of Fennec Pharmaceuticals Inc. stock.

On average, over the past 5 years, insiders at Fennec Pharmaceuticals Inc. have bought $52,301 and sold $4.06M worth of stock each year.

Highest buying activity among insiders over the last 12 months: Hackman Jeffrey S. (Chief Executive Officer) — $104,602.

The last purchase of 13,965 shares for transaction amount of $97,615 was made by Hackman Jeffrey S. (Chief Executive Officer) on 2025‑05‑19.

List of Insider Buy and Sell Transactions, Fennec Pharmaceuticals Inc.

2026-01-02SaleRaykov Rostydirector
10,312
0.0369%
$7.60
$78,371
-1.30%
2025-12-24SaleSouthpoint Capital Advisors LP10 percent owner
1M
3.5493%
$7.50
$7.5M
-0.91%
2025-12-05SaleRaykov Rostydirector
10,000
0.0362%
$7.54
$75,400
+0.79%
2025-11-18SaleSouthpoint Capital Advisors LP10 percent owner
19,341
0.0705%
$8.79
$170,048
-12.69%
2025-11-17SaleSouthpoint Capital Advisors LP10 percent owner
85,918
0.3133%
$8.79
$755,193
-12.69%
2025-11-14SaleSouthpoint Capital Advisors LP10 percent owner
160,100
0.606%
$8.00
$1.28M
-2.67%
2025-11-05SaleRaykov Rostydirector
10,000
0.036%
$8.10
$81,000
-6.91%
2025-10-10SaleRALLIS CHRIS Adirector
1,775
0.007%
$9.24
$16,401
-9.22%
2025-10-09SaleSouthpoint Capital Advisors LP10 percent owner
20,609
0.0751%
$9.35
$192,614
-16.61%
2025-10-08SaleSouthpoint Capital Advisors LP10 percent owner
19,605
0.0733%
$9.47
$185,722
-15.62%
2025-10-07SaleSouthpoint Capital Advisors LP10 percent owner
26,900
0.099%
$9.59
$257,893
-17.62%
2025-10-06SaleRaykov Rostydirector
10,000
0.0365%
$9.78
$97,800
-19.51%
2025-09-04SaleRaykov Rostydirector
10,000
0.0354%
$8.92
$89,200
-11.44%
2025-08-05SaleRaykov Rostydirector
10,000
0.0359%
$8.09
$80,900
+0.92%
2025-07-07SaleRALLIS CHRIS Adirector
1,119
0.0042%
$8.71
$9,746
-0.83%
2025-07-03SaleRaykov Rostydirector
10,000
0.0354%
$8.61
$86,100
-4.49%
2025-06-05SaleRaykov Rostydirector
10,000
0.0357%
$7.78
$77,800
+5.32%
2025-05-19PurchaseHackman Jeffrey S.Chief Executive Officer
13,965
0.0462%
$6.99
$97,615
+8.24%
2025-05-16SaleRaykov Rostydirector
16,667
0.0599%
$6.78
$113,002
+21.05%
2025-05-16PurchaseHackman Jeffrey S.Chief Executive Officer
1,035
0.0037%
$6.75
$6,986
+21.05%
Total: 175
*Gray background shows transactions not older than one year

Insider Historical Profitability

3.09%
Southpoint Capital Advisors LP10 percent owner
2744741
9.9629%
$20.83M38
+14.67%
Raykov Rostydirector
88020
0.3195%
$668,071.80131
RALLIS CHRIS Adirector
57079
0.2072%
$433,229.61015
Hackman Jeffrey S.Chief Executive Officer
15000
0.0544%
$113,850.0020
Butts Robert W
41504000
150.6513%
$315.02M10
Essetifin SPA10 percent owner
3993694
14.4963%
$30.31M20
+12.47%
MANCHESTER MANAGEMENT CO LLC10 percent owner
2017357
7.3226%
$15.31M420
MANCHESTER MANAGEMENT PR, LLC10 percent owner
1250000
4.5373%
$9.49M3716
<0.0001%
Andrade RobertCHIEF FINANCIAL OFFICER
104271
0.3785%
$791,416.89110
Haigh AdrianCHIEF OPERATING OFFICER
0
0%
$006
*Gray background shows insiders who have made transactions during last year

Historical Insider Profitability vs. Competitors

$22,693,451
105
8.15%
$196M
$7,508,580
92
-5.61%
$217.21M
$18,994,888
46
88.59%
$194M
$2,402,219
34
24.09%
$197.67M
$109,415,500
33
18.13%
$235.33M
$1,037,470
13
78.00%
$207.14M
$135,589,307
10
32.46%
$213.86M
$6,847,110
9
5.96%
$198.17M
$13,043,783
8
732.82%
$211.78M
$127,235
8
-12.15%
$238.28M
$91,549,696
8
-6.55%
$233M
$145,296,407
8
-0.98%
$209.06M
$5,905,507
7
2.69%
$204.48M
$119,637,899
7
-18.65%
$222.27M
Fennec Pharmaceuticals Inc.
(FENC)
$8,286,963
6
3.09%
$209.1M
$46,740
5
-73.90%
$247.35M
$16,003,671
3
55.38%
$193.39M
$32,289,200
3
-5.46%
$200.84M
$802,500
1
5.37%
$238.06M

FENC Institutional Investors: Active Positions

Increased Positions39+48.75%777,506+5.72%
Decreased Positions29-36.25%508,529-3.74%
New Positions13New73,868New
Sold Out Positions5Sold Out157,326Sold Out
Total Postitions90+12.5%14M+1.98%

FENC Ownership Change vs Market

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
Southpoint Capital Advisors Lp$31,313.0012.36%4.08M00%2025-09-30
Solas Capital Management, Llc$16,803.006.63%2.19M-45,000-2.02%2025-09-30
Rosalind Advisors, Inc.$15,950.006.29%2.08M+31,196+1.52%2025-09-30
Blackrock, Inc.$9,307.003.67%1.21M-14,631-1.19%2025-09-30
Vanguard Group Inc$7,340.002.9%955,764-11,328-1.17%2025-09-30
Aigh Capital Management Llc$5,234.002.07%681,501+229,101+50.64%2025-09-30
State Street Corp$2,620.001.03%341,201+4,707+1.4%2025-09-30
Tang Capital Management Llc$2,570.001.01%334,593+314,066+1,530.01%2025-09-30
Geode Capital Management, Llc$2,310.000.91%300,772-3,825-1.26%2025-09-30
Morgan Stanley$1,785.000.7%232,402-21,816-8.58%2025-09-30

Financial Ratios

Summary
Comparison with Competitors

Price to Earnings

Price/Earnings to Growth

Price to Sales

Price to Book

Price/Free Cash Flow

Analyst Recommendations

Analyst Price Targets

Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.